# A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

> **NCT05848440** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 48 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis

## Interventions

- **DRUG:** AZD9550
- **DRUG:** AZD9550
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05848440
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-02
- **Primary completion:** 2023-11-13
- **Final completion:** 2023-11-13
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05848440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05848440, "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05848440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*